. Although over one-third of all breast cancers are diagnosed among women aged 65-79 years, little epidemiologic research has specifically focussed on breast cancer in women of this age. Women of this age also commonly suffer from hypertension or coronary disease, and calcium channel blockers (CCBs) are often used to treat either of these conditions. Two recent studies, yet to be published, of women aged 65 and older, suggest that women who use CCBs may be at an increased risk of breast cancer. This suspected association is given biological plausibility by the observation that pharmacological blockade of the calcium channels can inhibit apoptosis (programmed cell death), the process whereby organisms eliminate unwanted cells (e.g., preneoplastic, initiated, damaged, excessive). In this sense, CCBs may be cancer promoters. The application proposes a case-control study of 1,000 women, aged 65-79, who reside in King County, Washington, who are on the Health Care Financing Administration (HCFA) tapes, and who are diagnosed with their first invasive breast cancer during the time period of January 1, 1997 through December 31, 1999. The personal interview responses of these women about drug use and other known risk factors for breast cancer will be compared to a control group of 1,000 women without breast cancer who will be identified through the HCFA tapes. Based on the preliminary studies and the evidence from in vitro studies on cells, it is posited that the use of CCBs increases the risk of breast cancer in older women. The plan is to assess whether calcium antagonists used in the treatment of hypertension and cardiovascular diseases promote breast cancer in women aged 65-79 years, and whether any one type of calcium channel blocker is more related to breast cancer than the other types. Since no studies have assessed present or past use of combined estrogen-progestin therapy in a large group of women this age, and the concurrent use of hormone replacement therapy (HRT) by these women may affect the proposed estimates of risk associated with CCBs, data will also be collected and analyzed on other drugs (viz., cimetidine, anti-depressants, lipid lowering drugs) frequently used by women in this age group.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA072787-04
Application #
6150243
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Program Officer
Verma, Mukesh
Project Start
1997-04-10
Project End
2001-07-31
Budget Start
2000-02-08
Budget End
2001-01-31
Support Year
4
Fiscal Year
2000
Total Cost
$515,275
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Resler, Alexa J; Malone, Kathleen E; Johnson, Lisa G et al. (2013) Genetic variation in TLR or NFkappaB pathways and the risk of breast cancer: a case-control study. BMC Cancer 13:219
Madeleine, Margaret M; Johnson, Lisa G; Malkki, Mari et al. (2011) Genetic variation in proinflammatory cytokines IL6, IL6R, TNF-region, and TNFRSF1A and risk of breast cancer. Breast Cancer Res Treat 129:887-99
Reding, Kerryn W; Weiss, Noel S; Chen, Chu et al. (2009) Genetic polymorphisms in the catechol estrogen metabolism pathway and breast cancer risk. Cancer Epidemiol Biomarkers Prev 18:1461-7
Reding, Kerryn W; Li, Christopher I; Weiss, Noel S et al. (2009) Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk. Am J Epidemiol 170:1241-9
Phipps, Amanda I; Malone, Kathleen E; Porter, Peggy L et al. (2008) Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 113:1521-6
Mathes, Robert W; Malone, Kathleen E; Daling, Janet R et al. (2008) Migraine in postmenopausal women and the risk of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 17:3116-22
Phipps, Amanda I; Malone, Kathleen E; Porter, Peggy L et al. (2008) Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17:2078-86
Li, Christopher I; Malone, Kathleen E; Daling, Janet R (2006) Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States). Cancer Causes Control 17:695-703
Li, Christopher I; Malone, Kathleen E; Daling, Janet R (2005) The relationship between various measures of cigarette smoking and risk of breast cancer among older women 65-79 years of age (United States). Cancer Causes Control 16:975-85
Boudreau, Denise M; Gardner, Jacqueline S; Malone, Kathleen E et al. (2004) The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 100:2308-16

Showing the most recent 10 out of 15 publications